2020.11_edited.jpg

TESTIMONIALS

What others are saying about our technologies

 
Blurred_Background_01.tiff

"AT THE ONCOIMMUNOLOGY UNIT OF NAVARRABIOMED WE DEVELOP LENTIVIRUS-BASED CANCER IMMUNOTHERAPIES. TO ACCELERATE OUR RESEARCH, WE NEED A FAST, REPRODUCIBLE, AND EASY-TO-USE VIRUS PURIFICATION METHOD. WE TESTED CAPTUVIR TO PURIFY A 100 MILLILITERS SAMPLE OF 0.45 µm-FILTERED LENTIVIRUS PREPARATIONS BOTH WITH AND WITHOUT FCS. COMPARED TO OTHER PURIFICATION METHODS SUCH AS PRECIPITATION OR CENTRIFUGATION THAT TAKE US ALMOST ONE DAY TO PERFORM, CAPTUVIR ALLOWED US TO CONCENTRATE OUR LENTIVIRUSES AROUND TEN TIMES WITH UP TO 70% RECOVERY IN ONLY ONE HOUR.

WE PARTICULARLY LIKED THE FACT THAT USING CAPTUVIR WAS SIMPLE AND THE PURIFICATIONS WERE REPRODUCIBLE.

WE WILL CONTINUE USING CAPTUVIR, ALSO FOR LARGER SAMPLE VOLUMES."

DR. GRAZYNA KOCHAN AND DR. DAVID ESCORS MURUGARREN, HEADS OF THE ONCOIMMUNOLOGY GROUP AT NAVARRABIOMED

Blurred_Background_01.tiff

"AT THE COPENHAGEN HEPATITIS C PROGRAM (CO-HEP) AT COPENHAGEN UNIVERSITY HOSPITAL, HVIDOVRE, WE ARE DEVELOPING INACTIVATED COVID-19 VACCINES. IN ORDER TO TEST THE EFFICACY OF OUR VACCINES IN ANIMALS, WE REQUIRE A ROBUST PURIFICATION AND CONCENTRATION METHOD THAT DOESN'T COMPROMISE THE BIOLOGICAL INTEGRITY OF THE PRODUCT AND THAT CAN COPE WITH THE RELATIVELY LARGE BATCH VOLUMES WE PRODUCE. 

USING CAPTUVIR, 300 MILLILITERS OF OUR INACTIVATED SARS-COV-2 PARTICLES WERE PURIFIED IN ONE HOUR USING A UNIVERSAL PROTOCOL AND SUCCESSFULLY TESTED IN ANIMALS. THANKS TO THESE ENCOURAGING RESULTS, AN ADDITIONAL 4.5 LITERS OF OUR VIRUS HARVESTS WERE PURIFIED WITH CAPTUVIR FOR FURTHER ANIMAL TESTING. 

WE BELIEVE THAT CAPTUVIR'S SXC TECHNOLOGY PROVIDES A SIGNIFICANT IMPROVEMENT OVER OTHER PURIFICATION METHODS, SUCH AS SUCROSE GRADIENTS, THAT ARE POORLY SCALABLE, SLOWER, AND SHOW LOW PRODUCT RECOVERY.

WE FEEL THAT CAPTUVIR WAS A CRITICAL TOOL THAT ALLOWED US TO ACCELERATE PRE-CLINICAL TESTING OF OUR VACCINE CANDIDATES AND WE RECOMMEND IT FOR THE PURIFICATION OF HUMAN CORONAVIRUSES."

PROF. JUDITH GOTTWEIN, MD, DR. MED

CO-HEP, DEPT. OF INFECTIOUS DISEASES, COPENHAGEN UNIVERSITY HOSPITAL, HVIDOVRE AND DEPARTMENT OF IMMUNOLOGY AND MICROBIOLOGY, FACULTY OF HEALTH AND MEDICAL SCIENCES OF COPENHAGEN